Blog

After over 1000 adverse event reports, several consumer watchdog groups have urged diabetics to avoid using Actos or its generic equivalent. Many have espoused that actos use may not be worth the associated health risks. A group by the name of “Consumer Reports” noted that Actos should only be used as a “last resort” diabetes drug.

A recent request was filed to centralize all New Jersey State Court Stryker Hip Implant claims in front of one judge for joint discovery and handling. Cases are often centralized to save litigation resources and expedite the overall litigation process. If approved, this request for centralization may be the first step in a potential MDL, multi-district litigation, for Stryker Hip Implant cases which would include not only New Jersey cases but also include cases throughout the nation.

Stryker Orthopaedics recalled its Rejuvenate hip system and ABG II modular-neck stems, both of which are popular components of many of its most popular hip implant systems. Both the Rejuvenate and ABG II modular-neck stems may be used with either metal or ceramic hip implants.

According to a new study published in the British Medicine Journal which compared healthy people with patients diagnosed with bladder cancer, Actos use has been associated with an 83% increased risk of bladder cancer and a 200% increased risk of bladder cancer if Actos is used for more than 2 years.

After being sued by over 600 women who claim that their transvaginal mesh products caused serious-life altering injuries, Johnson & Johnson’s Ethicon unit has decided to stop selling four of its most popular transvaginal mesh products and restrict the usage of other Gynecare mesh products.

MDL Consolidation to eliminate duplicative discovery, prevent inconsistent pretrial rulings, and conserve the resources of the parties, their counsel and the judiciary

Lisinopril (Prinivil & Zestril) Linked to Various Severe Adverse Effects

FDA Panel Recommends Label Changes to Reduce Risk of Problems from Fosamax

Propecia use has been linked to Erectile Dysfunction, General Sexual Dysfunction, Impotence, and Prostate Cancer

The FDA released a report in preparation for an Advisory Panel Meeting scheduled for September 9, 2011 to review and discuss the available data regarding the long-term (greater than 3 – 5 years) use of Fosamax for the treatment and/or prevention of osteoporosis.